Mark Chalmers is a director in Navigant’s Life Science Strategy practice, based in London. He has more than 10 years experience specializing in global commercial strategy and marketing, including international pricing and market access for pharmaceutical and biotech companies. He focuses on the healthcare systems of the EU member states and health technology assessment, with a deep knowledge of oncology, rare diseases, cell and gene based therapies.
He works closely with clients in the pharmaceutical and biotech industries to address critical commercial strategic issues and support business development and licensing decisions. Functional experience includes: product, portfolio, therapeutic area and market opportunity assessments; clinical trial design optimization; value proposition and message development; pricing, reimbursement, market access strategies; payer negotiation, contracting strategies and lifecycle management
Prior to Navigant, Mark was the Principal & EU lead at CBPartners for four years, where he was responsible for establishing the European business and heading its London office. Prior to that, Mark was a director at Simon-Kucher & Partners, where for five years he focused on the healthcare systems of the EU member states and in particular health technology assessment in the UK. Additionally, he worked for three years at Capgemini Consulting, working in sales and marketing in the healthcare and life sciences sector. He gained strategic consulting experience in the public, private and third sector.
Mark has a Ph.D in Pharmacology from the University of Cambridge where he investigated the pharmacology, molecular biology, genetics and intracellular signaling mechanisms of blood cells. He attained a first class Bsc (Hons) in Pharmacology with Industrial Experience from Edinburgh University, Scotland, where he also gained industrial pharmaceutical research experience with IQVIA.
+44 20 766 10557